# Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures

> **NCT03336242** · PHASE2 · TERMINATED · sponsor: **Radius Pharmaceuticals, Inc.** · enrollment: 20 (actual)

## Conditions studied

- Childhood Absence Epilepsy

## Interventions

- **DRUG:** Cannabidiol Oral Solution

## Key facts

- **NCT ID:** NCT03336242
- **Lead sponsor:** Radius Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-12-29
- **Primary completion:** 2019-05-15
- **Final completion:** 2019-05-29
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** More patients in Cohort 1 than Cohort 2 demonstrated a clinically meaningful reduction of seizure count. Given this, enrollment of Cohort 3 was discontinued.
- **Last updated:** 2023-07-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03336242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03336242, "Cannabidiol Oral Solution in Pediatric Participants With Treatment-Resistant Childhood Absence Seizures". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03336242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*